S-1 plus cisplatin: Another option in the treatment of advanced head and neck cancer?

Dok Hyun Yoon, Sung Bae Kim

Research output: Contribution to journalComment/debatepeer-review

5 Scopus citations


Evaluation of: Fujii M, Tomita K, Nishijima W et al. Phase I/II study of S-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer. Jpn. J. Clin. Oncol. 40(3), 214-221 (2010). A combination of 5-fluorouracil (5-FU) and cisplatin is the most commonly used chemotherapy regimen in patients with advanced head and neck cancer (HNC). Japanese investigators replaced 5-FU with the oral fluoropyrimidine S-1 (40 mg/m 2 twice daily on days 1-14 every 4 weeks) to treat patients with locally advanced, recurrent, or metastatic HNC; and determined that the dose of cisplatin on day 8 should be 70 mg/m2. The authors also studied the efficacy and safety of this regimen in a continuing Phase II trial. Treatment with S-1 plus cisplatin resulted in a confirmed response rate of 44.1% and a median overall survival duration of 16.7 months. The most common grade 3 or 4 adverse events included anorexia (26.5%), nausea (14.7%), and neutropenia/thrombocytopenia (11.8%). Despite inclusion of patients heterogeneous in disease status and incomplete response evaluation, this study demonstrated that S-1 in combination with cisplatin is feasible for treatment of advanced/recurrent HNC.

Original languageEnglish (US)
Pages (from-to)659-662
Number of pages4
JournalExpert Review of Anticancer Therapy
Issue number5
StatePublished - May 1 2010


  • Advanced head and neck cancer
  • Cisplatin
  • Phase I
  • Phase II
  • S-1


Dive into the research topics of 'S-1 plus cisplatin: Another option in the treatment of advanced head and neck cancer?'. Together they form a unique fingerprint.

Cite this